Fenwick represented Perceive Bio, a biotech company pioneering novel technologies and therapeutics in ophthalmology, in its $78 million Series B financing. The round was led by Johnson & Johnson Innovation with participation from Deerfield Management, Braidwell LP, the Retinal Degeneration Fund and Catalio Capital Management, LP.
Perceive Bio will use the new capital to advance diversified pipeline in ophthalmology. More information can be obtained from the company’s announcement.
The transaction was led by corporate partner Matthew Rossiter and associates Janiece Jenkins, Joanna Xu, Said Ertekin and Leeza Soulina.